{"title":"连续的、多模式的癌症治疗:选择性生物启动(OK-432)、细胞质和核损伤(FT-207和环磷酰胺)、修复抑制(博来霉素)、激活清洁和监测机制。","authors":"S Okuyama, H Mishina","doi":"","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":76727,"journal":{"name":"The science reports of the research institutes, Tohoku University. Ser. C, Medicine. Tohoku Daigaku","volume":"28 1-4","pages":"7-14"},"PeriodicalIF":0.0000,"publicationDate":"1981-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Consecutive, multimodal therapy of cancer: selective biological initiation (OK-432), cytoplasmic and nuclear damage (FT-207 and cyclophosphamide), inhibition of repair (bleomycin), and activation of cleansing and surveillance mechanisms.\",\"authors\":\"S Okuyama, H Mishina\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":76727,\"journal\":{\"name\":\"The science reports of the research institutes, Tohoku University. Ser. C, Medicine. Tohoku Daigaku\",\"volume\":\"28 1-4\",\"pages\":\"7-14\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The science reports of the research institutes, Tohoku University. Ser. C, Medicine. Tohoku Daigaku\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The science reports of the research institutes, Tohoku University. Ser. C, Medicine. Tohoku Daigaku","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Consecutive, multimodal therapy of cancer: selective biological initiation (OK-432), cytoplasmic and nuclear damage (FT-207 and cyclophosphamide), inhibition of repair (bleomycin), and activation of cleansing and surveillance mechanisms.